Acute Myeloid Leukemia Treatment Companies

Mirati Therapeutics' SPRYCEL® (dasatinib) receives expanded approval for newly diagnosed, FLT3 mutation-positive AML: This provides a targeted therapy option for a specific patient subset, improving treatment options.

Agios Pharmaceuticals' AG-221 receives breakthrough therapy designation for FLT3-mutated AML promising investigational drug holds potential for further improving outcomes in this patient population.

Several clinical trials are underway evaluating novel therapies, including CDK9 inhibitors, bispecific T-cell engagers (BiTEs), and CAR-T cell therapies innovative approaches could revolutionize AML treatment by targeting specific cancer pathways and boosting the immune system's response.

Novartis partners with MD Anderson Cancer Center on clinical trials for novel AML therapies collaborative effort combines Novartis' drug development expertise with the Center's research capabilities to accelerate the development of promising treatments.

Roche collaborates with academic institutions and patient advocacy groups on AML research and educational initiatives partnerships foster knowledge sharing, empower patients, and drive advancements in diagnosis and treatment.

List of Acute Myeloid Leukemia Treatment Key Companies in the Market

• Johnson & Johnson, Pfizer Inc.


• Celgene Corporation


• Ambit Biosciences Corporation


• Cyclacel Pharmaceuticals Inc.


• Novartis AG and Sanofi


• Bristol Myers Squibb